NIKKEI 225
37,806.43 +177.95 (+0.47%) HANG SENG
17,555.64 +271.10 (+1.57%) CRUDE OIL
83.81 +0.24 (+0.29%) GOLD FUTURES
2,345.80 +3.30 (+0.14%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,530.52 +202.52 (+0.39%)
Madrigal Pharmaceuticals, Inc. (0JXI.L)
| Previous close | 208.65 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 201 |
| Market cap | 30.499M |
| Beta (5Y monthly) | -0.44 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -14.65 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireMadrigal Statement on the Passing of Dr. Stephen Harrison
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We offer our deepest condolences to Stephen’s family for their loss. Stephen was a colleague and friend to so many of us at Madrigal. He worked tirelessly to improve the lives of people with nonalcoholic steatohepatitis (NASH), and his contributions to the field will touch countless families across the globe for decades to come. So many of the recent in
- GlobeNewswire
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceut
- GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 7 new employees, in each case with a grant date of April 15, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The equity a
